Eczema (Atopic Dermatitis)

Eczema makes the skin’s barrier leak. Moisture escapes, irritants get in, and the immune system overreacts — producing the red, dry, intensely itchy patches that define the condition. It affects 10–20% of children and 1–3% of adults, and for many people it never fully goes away. Treatment is about managing flares and rebuilding the barrier between them.

Conventional approaches rely on emollients to restore moisture and topical steroids to suppress inflammation. Peat therapy offers a complementary route: it addresses inflammation, barrier damage, and itching simultaneously — and it does so through compounds that are naturally compatible with the skin’s own chemistry.

Why peat may help

Eczema is fundamentally a two-part problem: a leaky skin barrier and an overactive immune response. Peat works on both.

Calming the immune overreaction. In eczema, the immune system produces excess inflammatory signals — particularly the chemokines CCL17 and CCL22, which recruit immune cells to the skin and drive the itch-inflammation cycle. Fulvic acids directly suppress these chemokines by deactivating the p38 MAPK and JNK pathways in skin cells (Wu 2023). In a mouse model of atopic dermatitis, topical fulvic acid reduced ear swelling, redness, and blood levels of CCL17/CCL22 in a dose-dependent manner. Humic acids add a broader anti-inflammatory effect: they suppress TNF-α, IL-6, and IL-1β, while increasing the protective anti-inflammatory signal IL-10 (Verrillo 2022, Zhernov 2020).

Stopping the itch. The itch-scratch cycle is what turns mild eczema into severe eczema. Scratching damages the barrier further, which triggers more inflammation, which causes more itching. Fulvic acids interrupt this cycle at the source: they inhibit histamine release from mast cells — the same mechanism that antihistamine drugs target, but delivered topically (Yamada 2007). This anti-pruritic effect provides relief without the drowsiness associated with oral antihistamines.

Supporting the barrier. Peat’s moisturizing mechanism works on three levels: polysaccharides act as humectants that attract and hold water, waxes and lipids provide emollient softening, and the peat matrix itself creates a temporary occlusive layer that slows moisture loss. Crucially, peat’s natural acidity (pH 3.5–5.5) is compatible with the skin’s acid mantle — this matters more for eczema patients, whose barrier is already compromised by alkaline soaps and environmental exposure.

What the evidence says

The evidence for peat in eczema management is moderate — stronger than for most skin conditions, but still limited by study design.

Clinical observations from Central European spa settings report improvements in SCORAD scores (the standard eczema severity measure) after 2–3 week courses of peat baths. A review by Wollina (2009) supports humic substances as adjuncts in topical therapy of inflammatory skin diseases including atopic dermatitis. A broader review of peloid therapy for dermatological conditions (Gams 2020) confirms the immunomodulatory benefits observed in clinical practice.

Lab evidence is more specific. Zhernov (2020) showed that topical peloid-derived humic acid suppressed a wide range of inflammatory cytokines — IFN-γ, IL-4, IL-10, IL-13, IL-17, and TNF-α — in a mouse model of allergic contact dermatitis. Wu (2023) demonstrated that fulvic acid attenuated atopic dermatitis in mice through a clear molecular pathway: inhibiting p38 MAPK and JNK signalling in keratinocytes.

What’s missing: Large randomised controlled trials in human eczema patients comparing peat therapy to placebo or standard treatment. The existing evidence comes from cohort studies, clinical observations, and animal models. It’s also difficult to separate peat-specific effects from the general benefits of spa therapy — the stress reduction, climate change, and structured routine of a treatment course all contribute to improvement.